BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 11332169)

  • 1. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.
    Nordeng H; Lindemann R; Perminov KV; Reikvam A
    Acta Paediatr; 2001 Mar; 90(3):288-91. PubMed ID: 11332169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: case report and literature review].
    Agut-Quijano T; Martínez-Nadal S; Elizari-Saco MJ; Sala-Castellví P; Vila-Cerén C; Raspall-Torrent F
    Rev Neurol; 2006 Jun 1-15; 42(11):660-2. PubMed ID: 16736401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal complications after intrauterine exposure to SSRI antidepressants.
    Prescrire Int; 2004 Jun; 13(71):103-4. PubMed ID: 15233148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
    Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
    J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Maternal Pharmacogenetics Impact the Neonatal Abstinence Syndrome Following In Utero Exposure to Antidepressant Medications?
    Shea AK; Wang DY; Snelgrove JW; Dalfen A; Hewko S; Murphy KE
    J Obstet Gynaecol Can; 2021 Jun; 43(6):726-732. PubMed ID: 33303407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis.
    Sanz EJ; De-las-Cuevas C; Kiuru A; Bate A; Edwards R
    Lancet; 2005 Feb 5-11; 365(9458):482-7. PubMed ID: 15705457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.
    Levinson-Castiel R; Merlob P; Linder N; Sirota L; Klinger G
    Arch Pediatr Adolesc Med; 2006 Feb; 160(2):173-6. PubMed ID: 16461873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy].
    Cissoko H; Swortfiguer D; Giraudeau B; Jonville-Béra AP; Autret-Leca E
    Arch Pediatr; 2005 Jul; 12(7):1081-4. PubMed ID: 15964522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal adaptation in infants prenatally exposed to antidepressants--clinical monitoring using Neonatal Abstinence Score.
    Forsberg L; Navér L; Gustafsson LL; Wide K
    PLoS One; 2014; 9(11):e111327. PubMed ID: 25365553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.
    Eke AC; Saccone G; Berghella V
    BJOG; 2016 Nov; 123(12):1900-1907. PubMed ID: 27239775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine and neonatal withdrawal syndrome.
    Pogliani L; Schneider L; Dilillo D; Penagini F; Zuccotti GV
    BMJ Case Rep; 2010 Apr; 2010():. PubMed ID: 22736561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?
    Haddad PM; Pal BR; Clarke P; Wieck A; Sridhiran S
    J Psychopharmacol; 2005 Sep; 19(5):554-7. PubMed ID: 16166193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of newer antidepressants in pregnancy.
    Way CM
    Pharmacotherapy; 2007 Apr; 27(4):546-52. PubMed ID: 17381382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review.
    Tuccori M; Testi A; Antonioli L; Fornai M; Montagnani S; Ghisu N; Colucci R; Corona T; Blandizzi C; Del Tacca M
    Clin Ther; 2009 Jun; 31 Pt 1():1426-53. PubMed ID: 19698902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perinatal outcome following third trimester exposure to paroxetine.
    Costei AM; Kozer E; Ho T; Ito S; Koren G
    Arch Pediatr Adolesc Med; 2002 Nov; 156(11):1129-32. PubMed ID: 12413342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal Withdrawal Syndrome following Late in utero Exposure to Selective Serotonin Reuptake Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies.
    Wang J; Cosci F
    Psychother Psychosom; 2021; 90(5):299-307. PubMed ID: 33971648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database.
    Gastaldon C; Arzenton E; Raschi E; Spigset O; Papola D; Ostuzzi G; Moretti U; Trifirò G; Barbui C; Schoretsanitis G
    Psychol Med; 2023 Sep; 53(12):5645-5653. PubMed ID: 36128628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].
    de Moor RA; Mourad L; ter Haar J; Egberts AC
    Ned Tijdschr Geneeskd; 2003 Jul; 147(28):1370-2. PubMed ID: 12892015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine].
    Salvia-Roigés MD; Garcia L; Goncé-Mellgren A; Esqué-Ruiz MT; Figueras-Aloy J; Carbonell-Estrany X
    Rev Neurol; 2003 Apr 16-30; 36(8):724-6. PubMed ID: 12717649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.